SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Por:
Gonzalez-Cao, M, Puertolas, T, Martinez-Vila, C, Carrera, C, Seral, CM, Rodriguez-Jimenez, P, Sequero, S, Cerezuela-Fuentes, P, Ochoa, RF, Munoz, E, Basa, MA, Martin-Liberal, J, Soria, A, Moreno, JFR, Marquez-Rodas, I, Criado, PL, Manzano, JL, Lopez-Castro, R, De Miguel, PA, Villalobos, L, Algarra, SM, Gonzalez-Barrallo, I, Boada, A, Castano, AG, Puig, S, Crespo, G, Fra, PL, Zamora, CA, Rodriguez, MF, Valles, L, Drozdowskyj, A, Gardeazabal, J, Fernandez-Morales, LA, Rodrigo, A, Cruz, R, Yelamos, O, Rubio, B, Mujica, K, Provencio, M, Berrocal, A
Publicada:
1 ene 2023
Ahead of Print:
1 dic 2022
Resumen:
Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( "GRAVID ").Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.Results One hundred-fifty cases were registered. Median age was 68 years (range 6-95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February-May 2020, August-November 2020, and December 2020-April 2021. The first wave had the highest number of registered cases and COVID-19 mortality.Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection.
Filiaciones:
Gonzalez-Cao, M:
Dexeus Univ Hosp, Inst Oncol Dr Rosell, Translat Canc Res Unit, C Sabino Arana 5, Barcelona 080028, Spain
Puertolas, T:
Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain
Martinez-Vila, C:
Xarxa Assistencial Univ Manresa, Fdn Althaia, Barcelona, Spain
Carrera, C:
Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Melanoma Grp IDIBAPS,Dermatol Dept, Barcelona, Spain
Seral, CM:
Hosp Univ Cent Asturias, Oviedo, Spain
Rodriguez-Jimenez, P:
Hosp Univ La Princesa, Dermatol Dept, Madrid, Spain
Sequero, S:
Hosp San Cecilio, Med Oncol Dept, Granada, Spain
Cerezuela-Fuentes, P:
Hosp Clin Univ Virgen Arrixaca, Med Oncol Dept, Murcia, Spain
Ochoa, RF:
Hosp Univ La Paz, Madrid, Spain
Munoz, E:
Hosp Univ Vall dHebron, Med Oncol Dept, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Barcelona, Spain
Basa, MA:
Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain
Martin-Liberal, J:
Catalan Inst Oncol ICO Hosp, Med Oncol Dept, Barcelona, Spain
Soria, A:
Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain
Moreno, JFR:
Ctr Integral Oncol HM Clara Campal, Med Oncol Dept, Madrid, Spain
Marquez-Rodas, I:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
CIBERONC, Madrid, Spain
Criado, PL:
Hosp MD Anderson, Med Oncol Dept, Madrid, Spain
Manzano, JL:
Germans Trias & Pujol Res Inst & Hosp IGTP, Catalonian Inst Oncol ICO Badalona, Med Oncol Dept, Barcelona, Spain
Lopez-Castro, R:
HCU Valladolid, Med Oncol Dept, Valladolid, Spain
De Miguel, PA:
Hosp San Pedro de Alcantara, Caceres, Spain
Villalobos, L:
Hosp Principe Asturias, Alcala De Henares, Spain
Algarra, SM:
Clin Univ Navarra, Med Oncol Dept, Pamplona, Spain
Gonzalez-Barrallo, I:
Hosp Clin Valencia, Valencia, Spain
Boada, A:
Hosp Germans Trias & Pujol Res Inst & Hosp IGTP, Dermatol Dept, Barcelona, Spain
Castano, AG:
Hosp Marques de Valdecilla, Med Oncol Dept, Santander, Spain
Puig, S:
Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Melanoma Grp IDIBAPS,Dermatol Dept, Barcelona, Spain
Crespo, G:
Hosp Univ Burgos, Burgos, Spain
Fra, PL:
Hosp Son Espases, Mallorca, Spain
Zamora, CA:
Hosp Univ Infanta Sofia, Madrid, Spain
Rodriguez, MF:
Hosp Univ La Paz, Madrid, Spain
Valles, L:
Hosp Gen Villalba, Madrid, Spain
Drozdowskyj, A:
Dexeus Univ Hosp, Inst Oncol Dr Rosell, Translat Canc Res Unit, C Sabino Arana 5, Barcelona 080028, Spain
Gardeazabal, J:
Hosp Cruces, Bilbao, Spain
Fernandez-Morales, LA:
Hosp Parc Tauli, Sabadell, Spain
Rodrigo, A:
Hosp Arnau Vilanova, Lleida, Spain
Cruz, R:
Hosp Univ Nuestra Senora de la Candelaria, Santa Cruz De Tenerife, Spain
Yelamos, O:
Hosp Santa Creu & Sant Pau, Dermatol Dept, Barcelona, Spain
Rubio, B:
Hosp Quiron, Oncol Dept, Madrid, Spain
Mujica, K:
Hosp Donostia, Donostia San Sebastian, Spain
Provencio, M:
Hosp Puerta de Hierro, Madrid, Spain
Berrocal, A:
Hosp Univ Gen Valencia, Valencia, Spain
Bronze, Green Published, Green
|